DK2958941T3 - Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom - Google Patents

Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom Download PDF

Info

Publication number
DK2958941T3
DK2958941T3 DK14706017.2T DK14706017T DK2958941T3 DK 2958941 T3 DK2958941 T3 DK 2958941T3 DK 14706017 T DK14706017 T DK 14706017T DK 2958941 T3 DK2958941 T3 DK 2958941T3
Authority
DK
Denmark
Prior art keywords
periferted
microom
kir3dl2
cell
treatment
Prior art date
Application number
DK14706017.2T
Other languages
English (en)
Inventor
Cécile Bonnafous
Hélène Sicard
Renaud Buffet
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma filed Critical Innate Pharma
Application granted granted Critical
Publication of DK2958941T3 publication Critical patent/DK2958941T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK14706017.2T 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom DK2958941T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361766798P 2013-02-20 2013-02-20
US201361831809P 2013-06-06 2013-06-06
PCT/EP2014/053340 WO2014128221A1 (en) 2013-02-20 2014-02-20 A compound that specifically binds to kir3dl2 for use in the treatment of peripheral t cell lymphoma

Publications (1)

Publication Number Publication Date
DK2958941T3 true DK2958941T3 (da) 2019-06-24

Family

ID=50156759

Family Applications (3)

Application Number Title Priority Date Filing Date
DK14706017.2T DK2958941T3 (da) 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
DK19163475.7T DK3521312T3 (da) 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
DK21166926.2T DK3896088T3 (da) 2013-02-20 2014-02-20 Behandling af perifert t-cellelymfom

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK19163475.7T DK3521312T3 (da) 2013-02-20 2014-02-20 Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
DK21166926.2T DK3896088T3 (da) 2013-02-20 2014-02-20 Behandling af perifert t-cellelymfom

Country Status (9)

Country Link
US (5) US20160002345A1 (da)
EP (3) EP3896088B1 (da)
JP (1) JP6360077B2 (da)
CN (1) CN105026427B (da)
AU (1) AU2014220668B2 (da)
CA (1) CA2899241C (da)
DK (3) DK2958941T3 (da)
ES (2) ES2730011T3 (da)
WO (1) WO2014128221A1 (da)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2859017T3 (pl) 2012-06-08 2019-07-31 Sutro Biopharma, Inc. Przeciwciała zawierające swoiste dla miejsca, niewystępujące naturalnie reszty aminokwasowe, sposoby ich wytwarzania i sposoby ich zastosowania
WO2014004639A1 (en) 2012-06-26 2014-01-03 Sutro Biopharma, Inc. Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
RU2682449C2 (ru) 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US20160130346A1 (en) * 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
US10280222B2 (en) 2014-03-14 2019-05-07 Innate Pharma Humanized antibodies with increased stability
WO2016030488A1 (en) * 2014-08-27 2016-03-03 Innate Pharma Treatment of celiac disease
CA2988912C (en) 2015-06-10 2023-09-12 National Research Council Of Canada Carbonic anhydrase ix-specific antibodies and uses thereof
AU2016299166B2 (en) 2015-07-24 2022-03-31 Innate Pharma Methods for detecting tissue infiltrating NK cells
SG11201806419RA (en) 2016-01-27 2018-08-30 Sutro Biopharma Inc Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
US11299543B2 (en) * 2016-06-02 2022-04-12 Bristol-Myers Squibb Company Use of an anti-PD-1 antibody in combination with an anti-CD30 antibody in cancer treatment
US20190248895A1 (en) * 2016-10-21 2019-08-15 Innate Pharma Treatment with anti-kir3dl2 agents
US20200207859A1 (en) * 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
CN108319816B (zh) * 2018-02-27 2021-04-23 广州大学 一种基于基因通路识别小分子核糖核酸的方法
CA3125945A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma
JP2024513880A (ja) * 2021-04-05 2024-03-27 イナート・ファルマ・ソシエテ・アノニム 免疫組織化学法およびｋｉｒ３ｄｌ２特異的薬剤

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5776427A (en) 1992-03-05 1998-07-07 Board Of Regents, The University Of Texas System Methods for targeting the vasculature of solid tumors
US5599790A (en) * 1992-06-11 1997-02-04 The Scripps Research Institute Fibrinogen γ chain polypeptide and compositions thereof
AU717020B2 (en) 1996-05-03 2000-03-16 Immunomedics Inc. Targeted combination immunotherapy of cancer
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
HU230769B1 (hu) 1999-01-15 2018-03-28 Genentech Inc. Módosított effektor-funkciójú polipeptid-változatok
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
SK287400B6 (sk) 1999-09-25 2010-08-09 University Of Iowa Research Foundation Prostriedok s obsahom imunostimulačnej nukleovej kyseliny a jeho použitie na stimuláciu imunitnej reakcie
WO2002050122A2 (en) 2000-12-18 2002-06-27 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Means for the diagnosis and therapy of ctcl
IL160358A0 (en) * 2001-08-23 2004-07-25 Genmab As Human antibodies specific for interleukin 15 (il-15)
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
EA200401325A1 (ru) 2002-04-09 2005-04-28 Киова Хакко Когио Ко., Лтд. Клетки с модифицированным геномом
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
AR040996A1 (es) 2002-08-19 2005-04-27 Coley Pharm Group Inc Acidos nucleicos inmunoestimuladores
JP2004126818A (ja) 2002-09-30 2004-04-22 Toshiba Corp 電子機器システム、電池ユニットおよび電池ユニットの動作制御方法
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US7803376B2 (en) * 2003-07-24 2010-09-28 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using NK cell potentiating compounds
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
SG173322A1 (en) 2004-04-16 2011-08-29 Macrogenics Inc Dw Us Fc gammad riib - specific antibodies and methods of use thereof
WO2005110474A2 (en) 2004-05-10 2005-11-24 Macrogenics, Inc. HUMANIZED FcϜRIIB SPECIFIC ANTIBODIES AND METHODS OF USE THEREOF
EP2287195B1 (en) * 2004-07-01 2019-05-15 Novo Nordisk A/S Pan-kir2dl nk-receptor antibodies and their use in diagnostik and therapy
EP1810035A4 (en) 2004-11-10 2010-03-17 Macrogenics Inc GENERATION OF FC ANTIBODY REGIONS FOR EFFECTOR FUNCTION
CN101103043A (zh) * 2005-01-06 2008-01-09 诺和诺德公司 Kir结合剂和使用其的方法
US20090208500A1 (en) 2005-06-03 2009-08-20 Genentech, Inc. Method of producing antibodies with improved function
HUE029465T2 (en) 2005-08-10 2017-02-28 Macrogenics Inc Identification and engineering of antibodies with variant Fc regions and methods of using same
FR2894982A1 (fr) 2005-12-16 2007-06-22 Lab Francais Du Fractionnement Procede de preparation d'anticorps selectifs des recepteurs fc activateurs
WO2007071829A2 (en) 2005-12-22 2007-06-28 Dermagene Oy Methods and means related to diseases
BRPI0707290A2 (pt) 2006-01-17 2011-08-16 Biolex Therapeutics Inc composições e métodos para humanização e otimização de n-glicanas em plantas
CA2644903A1 (en) 2006-03-10 2007-09-20 Macrogenics, Inc. Identification and engineering of antibodies with variant heavy chains and methods of using same
US7786270B2 (en) 2006-05-26 2010-08-31 Macrogenics, Inc. Humanized FcγRIIB-specific antibodies and methods of use thereof
WO2008002933A2 (en) 2006-06-26 2008-01-03 Macrogenics, Inc. Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
CN101522716B (zh) * 2006-10-02 2013-03-20 瑞泽恩制药公司 抗人il-4受体的高亲和力人抗体
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
ES2539045T3 (es) * 2009-01-19 2015-06-25 Innate Pharma Anticuerpos anti-KIR3D
US20120282285A1 (en) * 2009-07-17 2012-11-08 Rigshospitalet Masp isoforms as inhibitors of complement activation
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
WO2012006341A2 (en) * 2010-07-06 2012-01-12 Aveo Pharmaceuticals, Inc. Anti-ron antibodies
CA2881764C (en) * 2012-09-19 2022-08-16 Innate Pharma Kir3dl2 binding agents
RU2682449C2 (ru) 2012-09-19 2019-03-19 Иннейт Фарма Связывающие kir3dl2 агенты
DK2958941T3 (da) 2013-02-20 2019-06-24 Innate Pharma Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
US20160130346A1 (en) 2013-05-29 2016-05-12 Institut National De La Sante Et De La Recherche Medicale Kir3dl2 is a biomarker and a therapeutic target useful for respectively preventing and treating a subset of cutaneous and non-cutaneous peripheral t-cell lymphomas
US10280222B2 (en) 2014-03-14 2019-05-07 Innate Pharma Humanized antibodies with increased stability
US20190248895A1 (en) 2016-10-21 2019-08-15 Innate Pharma Treatment with anti-kir3dl2 agents
CA3125945A1 (en) 2019-01-22 2020-07-30 Innate Pharma Treatment of t cell lymphoma

Also Published As

Publication number Publication date
EP3896088B1 (en) 2025-07-23
DK3521312T3 (da) 2021-06-28
EP3521312B1 (en) 2021-04-07
EP2958941B1 (en) 2019-04-10
US20160002345A1 (en) 2016-01-07
US11078275B2 (en) 2021-08-03
AU2014220668A1 (en) 2015-08-20
EP3896088A1 (en) 2021-10-20
US20250092130A1 (en) 2025-03-20
CN105026427B (zh) 2019-12-24
AU2014220668B2 (en) 2018-12-13
ES2878749T3 (es) 2021-11-19
CA2899241C (en) 2023-03-28
US10174112B2 (en) 2019-01-08
DK3896088T3 (da) 2025-09-29
JP6360077B2 (ja) 2018-07-18
US20190127463A1 (en) 2019-05-02
US20170298132A1 (en) 2017-10-19
WO2014128221A1 (en) 2014-08-28
CN105026427A (zh) 2015-11-04
ES2730011T3 (es) 2019-11-07
EP2958941A1 (en) 2015-12-30
CA2899241A1 (en) 2014-08-28
JP2016513104A (ja) 2016-05-12
US20210363248A1 (en) 2021-11-25
EP3521312A1 (en) 2019-08-07
US12084498B2 (en) 2024-09-10

Similar Documents

Publication Publication Date Title
DK2958941T3 (da) Forbindelse, der binder specifikt til kir3dl2, til anvendelse til behandling af perifert t-cellelymfom
DK3006568T3 (da) Fremgangsmåde til fremstilling af tagatose
DK3083540T3 (da) Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner
DK3090171T3 (da) Forbedringer relateret til komponenthåndtering, særligt vindmøllekomponenthåndtering
DK3611262T3 (da) Fremgangsmåder til sekvensering af immunrepertoire
DK2970729T3 (da) Klæbemiddelsammensætning
DK3054976T3 (da) Anvendelse af semaphorin-4d-bindende molekyler til behandling af aterosklerose
BR112014016855A2 (pt) soluções aglutinantes
EP2921528A4 (en) ADHESIVE COMPOSITION
DK2992104T3 (da) Fremgangsmåde til ekspression
DK3010895T3 (da) Fremgangsmåde til fremstilling af 4-propargyleret aminobenzoxazinoner
DK3038656T3 (da) Forbindelse af glycosaminoglycan, fremgangsmåde til fremstilling og anvendelse deraf
EP2889351A4 (en) ADHESIVE COMPOSITION
EP2886622A4 (en) ADHESIVE COMPOSITION
DK3222274T3 (da) Sammensætninger og fremgangsmåder under anvendelse af capsider, der er resistente over for hydrolaser
DK3065790T3 (da) Fremgangsmåder til fjernelse af alpha-galactose
DK3511004T3 (da) Kombineret præparat til behandling af cancer
EP3012306A4 (en) ADHESIVE COMPOSITION
DK3038633T3 (da) Stabile polypeptider der binder til human komplement c5
DK3052102T3 (da) Sammensætninger til behandling af cancere
DK3137622T3 (da) Fremgangsmåder til at reducere tilbagegang af vitalkapacitet
DK2956254T3 (da) Bertlepåsætningsstykke til udvidelse af cylindriske rørender
EP3012305A4 (en) ADHESIVE COMPOSITION
EP3012303A4 (en) ADHESIVE COMPOSITION
DK2951552T3 (da) Opfangningsanordning til engangsbrug